Treatment of Genitourinary Syndrome of Menopause in Breast Cancer and Gynecologic Cancer Survivors: Retrospective Analysis of Efficacy and Safety of Vaginal Estriol, Vaginal Dehydroepiandrosterone and Ospemifene

키워드

참고문헌 (40)

1. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
2. "The 2022 Hormone Therapy Position Statement of The North American Menopause Society"Advisory Panel, "The 2022 hormone therapy position statement of The North American Menopause Society", Menopause, 29, pp.767~794 (2022)
3. Cameron CR, "The art of hormone replacement therapy(HRT)in menopause management", J Pharm Pract, 37, pp.736~740 (2024)
4. Deli T, "Hormone replacement therapy in cancer survivors-review of the literature", Pathol Oncol Res, 26, pp.63~78 (2020)
5. Sourouni M, "Hormone replacement therapy after gynaecological malignancies : a review article", Geburtshilfe Frauenheilkd, 81, pp.549~554 (2021)
6. Crean-Tate KK, "Management of genitourinary syndrome of menopause in female cancer patients : a focus on vaginal hormonal therapy", Am J Obstet Gynecol, 222, pp.103~113 (2020)
7. The NAMS 2020 GSM Position Statement Editorial Panel, "The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society", Menopause, 27, pp.976~992 (2020)
8. Faubion SS, "Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer : consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health", Menopause, 25, pp.596~608 (2018)
9. Chambers LM, "Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma", Int J Gynecol Cancer, 30, pp.515~524 (2020)
10. Santen RJ, "Systemic estradiol levels with low-dose vaginal estrogens", Menopause, 27, pp.361~370 (2020)
11. Crandall CJ, "Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study", Menopause, 25, pp.11~20 (2018)
12. Le Ray I, "Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients : a nested case-control study", Breast Cancer Res Treat, 135, pp.603~609 (2012)
13. Barton DL, "Systemic and local effects of vaginal dehydroepiandrosterone(DHEA) : NCCTG N10C1(Alliance)", Support Care Cancer, 26, pp.1335~1343 (2018)
14. Mension E, "Safety of prasterone in breast cancer survivors treated with aromatase inhibitors : the VIBRA pilot study", Climacteric, 25, pp.476~482 (2022)
15. Di Donato V, "Ospemifene for the treatment of vulvar and vaginal atrophy : a meta-analysis of randomized trials. Part I : evaluation of efficacy", Maturitas, 121, pp.86~92 (2019)
16. Di Donato V, "Ospemifene for the treatment of vulvar and vaginal atrophy : a meta-analysis of randomized trials. Part II : evaluation of tolerability and safety", Maturitas, 121, pp.93~100 (2019)
17. De Rosa N, "Impact of ospemifene on quality of life and sexual function in young survivors of cervical cancer : a prospective study", Biomed Res Int, 2017, pp.7513610~ (2017)
18. Kingsberg SA, "WISDOM survey : attitudes and behaviors of physicians toward vulvar and vaginal atrophy(VVA)treatment in women including those with breast cancer history", Menopause, 26, pp.124~131 (2019)
19. Biglia N, "Vaginal atrophy in breast cancer survivors : attitude and approaches among oncologists", Clin Breast Cancer, 17, pp.611~617 (2017)
20. Kingsberg SA, "The Women’s EMPOWER survey : identifying women’s perceptions on vulvar and vaginal atrophy and its treatment", J Sex Med, 14, pp.413~424 (2017)
21. Cucinella L, "Genitourinary syndrome of menopause in breast cancer survivors : current perspectives on the role of laser therapy", Int J Womens Health, 15, pp.1261~1282 (2023)
22. Crisp CC, "Validation of the Female Sexual Function Index(FSFI)for web-based administration", Int Urogynecol J, 26, pp.219~222 (2015)
23. Derogatis L, "Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder", J Sex Med, 5, pp.357~364 (2008)
24. Burholt V, "Short Form 36(SF-36)Health Survey Questionnaire : normative data for Wales", J Public Health(Oxf), 33, pp.587~603 (2011)
25. Steinert T, "PGI-I (patient’s global impression) as an outcome and quality indicator of psychiatric in-patient treatment: results and concordance with doctor’s assessments", Psychiatr Prax, 37, pp.343~349 (2010)
26. Mitchell CM, "Associations between improvement in genitourinary symptoms of menopause and changes in the vaginal ecosystem", Menopause, 25, pp.500~507 (2018)
27. Labrie F, "Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause", Menopause, 23, pp.243~256 (2016)
28. Portman DJ, "Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women", Menopause, 22, pp.1289~1295 (2015)
29. Portman DJ, "Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy", Menopause, 20, pp.623~630 (2013)
30. Archer DF, "Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness : a phase 3, randomized, double-blind, placebo-controlled, multicenter trial", Menopause, 26, pp.611~621 (2019)
31. Martel C, "Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks", J Steroid Biochem Mol Biol, 159, pp.142~153 (2016)
32. Melisko ME, "Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer : a randomized clinical trial", JAMA Oncol, 3, pp.313~319 (2017)
33. Salvatore S, "Current challenges in the pharmacological management of genitourinary syndrome of menopause", Expert Opin Pharmacother, 24, pp.23~28 (2023)
34. Benini V, "New innovations for the treatment of vulvovaginal atrophy : an up-to-date review", Medicina (Kaunas), 58, pp.770~ (2022)
35. Angelou K, "The genitourinary syndrome of menopause : an overview of the recent data", Cureus, 12, pp.e7586~ (2020)
36. Briggs P, "Genitourinary syndrome of menopause", Post Reprod Health, 26, pp.111~114 (2020)
37. Nappi RE, "Vulvar and vaginal atrophy in four European countries : evidence from the European REVIVE Survey", Climacteric, 19, pp.188~197 (2016)
38. Moral E, "The impact of genitourinary syndrome of menopause on well-being, functioning, and quality of life in postmenopausal women", Menopause, 25, pp.1418~1423 (2018)
39. Davison SL, "The relationship between self-reported sexual satisfaction and general well-being in women", J Sex Med, 6, pp.2690~2697 (2009)
40. Wasnik VB, "Genitourinary syndrome of menopause : a narrative review focusing on its effects on the sexual health and quality of life of women", Cureus, 15, pp.e48143~ (2023)

관련 논문AI추천